SG11201810249YA - A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases - Google Patents

A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases

Info

Publication number
SG11201810249YA
SG11201810249YA SG11201810249YA SG11201810249YA SG11201810249YA SG 11201810249Y A SG11201810249Y A SG 11201810249YA SG 11201810249Y A SG11201810249Y A SG 11201810249YA SG 11201810249Y A SG11201810249Y A SG 11201810249YA SG 11201810249Y A SG11201810249Y A SG 11201810249YA
Authority
SG
Singapore
Prior art keywords
international
rule
dmard
pct
applicant
Prior art date
Application number
SG11201810249YA
Inventor
Salvatore Albani
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11201810249YA publication Critical patent/SG11201810249YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SEQID NO:--L--DMARD W O 20 17 / 200 489 Al Figure 7 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 November 2017 (23.11.2017) WIPO I PCT 0111111010 0111 inn III VIII ionoiflo oimIE (10) International Publication Number WO 2017/200489 Al (51) International Patent Classification: A61K 31/4706 (2006.01) A61P 19/02 (2006.01) A61K 38/04 (2006.01) (21) International Application Number: PCT/SG2017/050259 (22) International Filing Date: 18 May 2017 (18.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/338,319 18 May 2016 (18.05.2016) US (71) Applicant: SINGAPORE HEALTH SERVICES PTE. LTD. [SG/SG]; 31 Third Hospital Avenue, #03-03, Singa- pore 168753 (SG). (72) Inventor: ALBANI, Salvatore; 31 Third Hospital Avenue, #03-03, Singapore 168753 (SG). (74) Agent: YUSARN AUDREY; 24 Raffles Place, #27-01 Clifford Centre, SINGAPORE 048621 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) (54) Title: A PHARMACEUTICAL COMPOSITION AND THE USE THEREOF IN THE TREATMENT OF AUTOIMMUNE = DISEASES (57) : The present invention relates to compounds comprising formula I . Amino Acid Sequence-(L)„-DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1 ), DMARD is a disease modifying antirheumatic agent, L is a linker unit; - is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine. [Continued on next page] WO 2017/200489 Al MIDEDIMOMMIDIRMEM00101011111IMEHOMEMOIMIE Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201810249YA 2016-05-18 2017-05-18 A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases SG11201810249YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338319P 2016-05-18 2016-05-18
PCT/SG2017/050259 WO2017200489A1 (en) 2016-05-18 2017-05-18 A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
SG11201810249YA true SG11201810249YA (en) 2018-12-28

Family

ID=60326576

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810249YA SG11201810249YA (en) 2016-05-18 2017-05-18 A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases

Country Status (9)

Country Link
US (2) US11421000B2 (en)
EP (1) EP3458058A4 (en)
JP (1) JP6966053B2 (en)
KR (2) KR20230156367A (en)
CN (1) CN109475549B (en)
AU (1) AU2017265263B2 (en)
CA (1) CA3024575A1 (en)
SG (1) SG11201810249YA (en)
WO (1) WO2017200489A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021211923A1 (en) * 2020-04-16 2021-10-21 Pulmoquine Therapeutics, Inc. Compositions and methods for treating disease
CN113304281A (en) * 2021-05-28 2021-08-27 新乡医学院 Application of PD-1siRNA and chloroquine in preparation of medicine for treating rectal cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527467A (en) * 1998-10-20 2002-08-27 サルバトーレ・アルバーニ Methods for isolating, quantifying, characterizing and regulating antigen-specific T cells
JP2003504074A (en) * 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション Induction of a Th1-like response in vitro
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
EP2032151B1 (en) * 2006-06-01 2013-12-18 The Regents of the University of California Combination therapy method and formulation
JP5635512B2 (en) 2008-09-16 2014-12-03 カリエム・アーメド Chemically modified cell penetrating peptides for improved delivery of gene regulatory compounds
WO2010104617A2 (en) * 2009-01-23 2010-09-16 Salvatore Albani Novel methods to induce a state of immune tolerance
CN104655845A (en) * 2013-11-20 2015-05-27 南京亿特生物科技有限公司 Preparation of chemiluminescence immunoassay kit for detecting chloroquine

Also Published As

Publication number Publication date
WO2017200489A1 (en) 2017-11-23
JP2019516803A (en) 2019-06-20
EP3458058A4 (en) 2020-02-19
CN109475549A (en) 2019-03-15
CN109475549B (en) 2022-03-08
US20190161518A1 (en) 2019-05-30
US11802139B2 (en) 2023-10-31
US11421000B2 (en) 2022-08-23
AU2017265263B2 (en) 2023-08-31
US20220089645A1 (en) 2022-03-24
EP3458058A1 (en) 2019-03-27
KR20190008343A (en) 2019-01-23
AU2017265263A1 (en) 2018-12-20
KR20230156367A (en) 2023-11-14
JP6966053B2 (en) 2021-11-10
CA3024575A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811432WA (en) Rna for cancer therapy
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201808686VA (en) Synthesis of indazoles
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof